Targeting Sphingolipid Metabolism as an Approach for Combination Therapies in Haematological Malignancies

Alexander Lewis, Craig Wallington-Beddoe, Jason Powell, Stuart Pitson

Research output: Contribution to journalReview articlepeer-review

12 Citations (Scopus)

Abstract

Conventional chemotherapy-based drug combinations have, until recently, been the backbone of most therapeutic strategies for cancer. In a time of emerging rationale drug development, targeted therapies are beginning to be added to traditional chemotherapeutics to synergistically enhance clinical responses. Of note, the importance of pro-apoptotic ceramide in mediating the anti-cancer effects of these therapies is becoming more apparent. Furthermore, reduced cellular ceramide in favour of pro-survival sphingolipids correlates with tumorigenesis and most importantly, drug resistance. Thus, agents that manipulate sphingolipid metabolism have been explored as potential anti-cancer agents and have recently demonstrated exciting potential to augment the efficacy of anti-cancer therapeutics. This review examines the biology underpinning these observations and the potential use of sphingolipid manipulating agents in the context of existing and emerging therapies for haematological malignancies.

Original languageEnglish
Article number72
JournalCell Death Discovery
Volume4
Issue number1
DOIs
Publication statusPublished - 1 Dec 2018

Fingerprint Dive into the research topics of 'Targeting Sphingolipid Metabolism as an Approach for Combination Therapies in Haematological Malignancies'. Together they form a unique fingerprint.

Cite this